Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 05, 2023
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 28, 2022
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 24, 2022
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 04, 2015
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Journal: American journal of clinical oncology
Published: February 04, 2014
Showing 1-5 of 5
Last Updated: 09/26/2026